Schizophrenia

Medical Clinics of North America

Volumn 85, Issue 3, 2001, Pages 663-689

  Goff, Donald C ^a   Heckers, Stephan ^a   Freudenreich, Oliver ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; COCAINE; DOPAMINE RECEPTOR; HALOPERIDOL; KETAMINE; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; QUETIAPINE; RISPERIDONE;

BASAL GANGLION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; GENETIC PREDISPOSITION; HUMAN; NEUROCHEMISTRY; NEUROMODULATION; PATHOPHYSIOLOGY; PHENOMENOLOGY; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SMOKING; TARDIVE DYSKINESIA; TEMPORAL LOBE; THALAMUS;

EID: 0035029941     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70335-7     Document Type: Article

References (229)

1. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
2. Neuroleptic malignant syndrome: Review and analysis of 115 cases
3. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development
4. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
5. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients
6. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia
7. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
8. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development
9. Awareness of illness in schizophrenia and schizoaffective and mood disorders
10. Psychopathologic domains and insight in schizophrenia
11. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging
12. Positive and negative symptoms in schizophrenia: A critical reappraisal
13. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry
14. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions
15. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia
16. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia
17. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
18. Grieving and loss in parents with a schizophrenic child
19. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains
20. The nature and prevalence of depression in chronic schizophrenic in-patients
21. The human striatum in schizophrenia: II. Increased number of striatal neurons in schizophrenics
22. The experimental reproduction of amphetamine psychosis
23. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
24. Reduced neuronal size in posterior hippocampus of schizophrenic patients
25. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
26. Susceptibility loci for bipolar disorder: Overlap with inherited vulnerability to schizophrenia
27. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia
28. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia
29. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21
30. The temporolimbic system theory of positive schizophrenic symptoms
31. Characterization of schizophrenic patients who commit suicide
32. Brain morphology and schizophrenia: A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures
33. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome
34. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
35. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
36. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-22
37. Structural abnormalities in deficit and nondeficit schizophrenia
38. Attentional impairments in deficit and nondeficit forms of schizophrenia
39. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia
40. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia
41. PET and MRI of the thalamus in never-medicated patients with schizophrenia
42. Assertive community treatment: An update of randomized trials
43. Visual information processing impairments in deficit and nondeficit schizophrenia
44. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype
45. Schizophrenia: Neuroepidemiology review series
46. The genetic epidemiology of schizophrenia in a Finnish twin cohort: A population-based modeling study
47. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
48. Schizophrenia
49. Strong inference, theory testing, and the neuroanatomy of schizophrenia
50. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs
51. Does the chronic psychiatric patient understand plain English?
52. White matter reduction in the parahippocampal gyrus of patients with schizophrenia
53. Hippocampal pyramidal cell disarray in schizophrenia as a bilateral phenomenon
54. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics
55. The clinical and neuroendocrine features of psychotic depression
56. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
57. Limbic-cortical neuronal damage and the pathophysiology of schizophrenia
58. Hippocampal morphometry in schizophrenia by high dimensional brain mapping
59. Schizophrenia and anteroventral thalamic nucleus: Selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons
60. Dopamine in schizophrenia: A review and reconceptualization
61. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy
62. Increased temporal lobe glucose use in chronic schizophrenic patients
63. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: Contrasting pattern to striatal response
64. Mental disorders and use of cardiovascular procedures after myocardial infarction
65. Postmortem studies of the hippocampal formation in schizophrenia
66. Decline in the diagnosis of schizophrenia among first admissions to the Scottish mental hospitals from 1969-78
67. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
68. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography
69. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
70. Basal ganglia pathology in schizophrenia and tardive dyskinesia: An MRI quantitative study
71. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
72. Pain insensitivity in psychosis
73. Mini-mental state: A practical method of grading the cognitive state of patients for the clinician
74. Schizophrenia and nicotinic receptors
75. The left medial temporal region and schizophrenia: A PET study
76. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients
77. Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms
78. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
79. Hippocampal volume asymmetry and age at illness onset in males with schizophrenia
80. A comparison of academic and lay theories of schizophrenia
81. Obstetric complications and schizophrenia: A metaanalysis
82. Treating extrapyramidal reactions: Some current issues
83. Cigarette smoking: Implications for psychiatric illness
84. Negative symptoms in schizophrenia: Neurobiological models and treatment response
85. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia
86. Glutamate in schizophrenia: Clinical and research implications
87. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects
88. Psychotic patients
89. Psychotic exacerbations and enhanced secretion in schizophrenic patients with hyponatremia and polydipsia
90. Alterations in hippocampal mossy fiber pathway in schizophrenia and Alzheimer's disease
91. Confirming unexpressed genotypes for schizophrenia: Risks in the offspring of Fischer's Danish identical and fraternal twins
92. What are the functional consequences of neurocognitive deficits in schizophrenia?
93. Functional brain imaging studies in schizophrenia
94. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia: A postmortem study
95. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
96. Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia
97. Decrease hippocampal expression of a glutamate receptor gene in schizophrenia
98. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum
99. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems
100. Hippocampal neuron number in schizophrenia: A stereological study
101. Cortex, white matter, and basal ganglia in schizophrenia: A volumetric postmortem study
102. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
103. Clozapine for polydipsia and hyponatremia in chronic schizophrenics
104. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
105. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics
106. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites
107. Prenatal developmental disturbances in the limbic allocortex in schizophrenics
108. Recent advances in the phencyclidine model of schizophrenia
109. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
110. Subchronic phencyclidine administration increases mesolimbic dopamine system responsivity and augments stress and amphetamine-induced hyperlocomotion
111. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia
112. Tardive dyskinesia
113. Risk of tardive dyskinesia in older patients
114. Lower incidence of tardive dyskinesia with risperidone compared to haloperidol in older patients
115. The new epidemiology of schizophrenia
116. Schizophrenia as a long-term outcome of pregnancy, delivery and perinatal complications: A 28-year follow-up of the 1966 North Finland general population birth cohort
117. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
118. Incidence of tardive dyskinesia: Five-year data from a prospective study
119. Do negative symptoms respond to pharmacological treatment?
120. Regional cerebral blood flow in patients with schizophrenia: Relevance to symptom structures
121. SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test
122. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy
123. Schizophrenic disorders
124. Obstetric complications and schizophrenia: A case-control study based on standardized obstetric records
125. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
126. Changes in caudate volume with neuroleptic treatment
127. Decreased caudate volume in neuroleptic-naive psychotic patients
128. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
129. Mental illness in the biological and adoptive relatives of schizophrenic adoptees, findings relevant to genetic and environmental factors in etiology
130. The effect of neuroleptics on cognitive and psychomotor function
131. The schedule for the deficit syndrome: An instrument for research in schizophrenia
132. Pathophysiology of schizophrenia and the striatum
133. Depression in first-episode schizophrenia
134. Brain imaging in schizophrenia
135. A neurohistological correlate of schizophrenia
136. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
137. IBZM SPECT imaging of striatal dopamine2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol
138. Synaptic changes in the striatum of schizophrenic cases: A controlled postmortem ultrastructural study
139. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
140. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
141. The human striatum in schizophrenia: I. Increase in overall relative striatal volume in schizophrenics
142. Excess cancer mortality in Western Australian psychiatric patients due to highter case fatality rates
143. Brain abnormality in schizophrenia: A systemic and quantitative review of volumetric resonance imaging studies
144. General practitioners' attitudes to psychiatric and medical illness
145. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia
146. Serotonin 5-HT2 receptors in schizophrenia: A PET study using [18F] setoperone in neuroleptic-naive patients and normal subjects
147. The symptoms of chronic schizophrenia: A re-examination of the positive-negative dichotomy
148. Functional imaging - Schizophrenia
149. Patterns of cerebral blood flow in schizophrenia
150. Neuropsychiatric implications of basal ganglia dysfunction
151. Clozapine: Guidelines for clinical management
152. Duration of psychosis and outcome in first-episode schizophrenia
153. Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia
154. Study of a new schizophrenomimetic drug-sernyl
155. Hippocampal age-related changes in schizophrenia: A proton magnetic resonance spectroscopy study
156. Urbanization and psychosis: A study of 1942-1978 birth cohorts in the Netherlands
157. Risperidone in the treatment of schizophrenia
158. Low and conventional dose maintenance therapy with fluphenazine decanoate: Two year outcome
159. Medial temporal lobe structures in schizophrenia: Relationship of size to duration of illness
160. Characteristics of outcome in schizophrenia at 13 years
161. MRI anatomy of schizophrenia
162. Chemical and physiologic brain imaging in schizophrenia
163. Multiple-family groups and psychoeducation in the treatment of schizophrenia
164. Early detection and intervention in schizophrenia
165. Prenatal influenza infections and adult schizophrenia
166. Adult schizophrenia following prenatal exposure to an influenza epidemic
167. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
168. The importance of serotonin-dopamine interactions in the action of clozapine
169. The mechanism of action of novel antipsychotic drugs
170. Perceptual capacity, functions of the corpus striatum and schizophrenia
171. The initial prodrome in schizophrenia: Searching for core dimensions of experience and behavior
172. Mortality and causes of death in first admitted schizophrenic patients
173. Effects of family history and place and season of birth on the risk of schizophrenia
174. Psychotherapy for schizophrenia
175. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging
176. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
177. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
178. Communication difficulty of patients with schizophrenia and physical illness
179. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
180. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging
181. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: A 28-year follow-up
182. Reduction of the parahippocampal gyrus and the hippocampus in patients with chronic schizophrenia
183. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the epidemiologic catchment area (ECA) study
184. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study
185. The costs of schizophrenia: Assessing the burden
186. Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient
187. Basal ganglia role in behavior: Importance of sensory gating and its relevance to psychiatry
188. Relapse and rehospitalization during maintenance treatment of schizophrenia
189. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia
190. The medical psychiatrist as physician for the chronically mentally ill
191. Chemical brain anatomy in schizophrenia
192. Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients: A pilot MRI study
193. Abnormally high neuronal density in the schizophrenic cortex: A morphometric analysis of prefrontal area 9 and occipital area 17
194. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional stereologic counting method
195. Primary and drug-induced disorders of water homeostasis in psychiatric patients: Principles of diagnosis and management
196. A functional neuroanatomy of hallucinations in schizophrenia
197. Reduced GABA uptake sites in the temporal lobe in schizophrenia
198. Quetiapine in patients with schizophrenia
199. Dopamine receptors, neuroleptics and schizophrenia
200. On the topographical distribution of cortex lesions and anomalies in dementia praecox, with some account of their functional significance (part 1)
201. On the topographical distribution of cortex lesions and anomalies in dementia praecox, with some account of their functional significance (part 2)
202. The prediction of outcome in schizophrenia: II. Relationships between predictor and outcome variables: A report from the International Pilot Study of Schizophrenia
203. Schizophrenia after prenatal famine
204. Subcortical and temporal structures in affective disorder and schizophrenia: A magnetic resonance imaging study
205. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome
206. The deficit syndrome of schizophrenia: Towards heterogeneity
207. Schizophrenics and their adopted-away offspring: The Finnish adoptive study of schizophrenia
208. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
209. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
210. Seasonality of births in schizophrenia and bipolar disorder: A review of the literature
211. Geographical distribution of insanity in America: Evidence for an urban factor
212. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
213. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
214. Schizophrenia: Genes and environment
215. Risperidone: Efficacy and safety
216. Hippocampal volume in first-episode psychoses and chronic schizophrenia: A high-resolution magnetic resonance imaging study
217. Brain disease and psychiatric illness: When should a psychiatrist order a CAT scan?
218. The frontal lobes and schizophrenia
219. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: A magnetic resonance imaging and regional cerebral blood flow study of discordant monzygotic twins
220. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia
221. Adverse outcome of hip fractures in older schizophrenic patients
222. Factors in the development of severe forms of tardive dyskinesia
223. The hippocampus in schizophrenia: Lateralized increase in neuronal density and altered cytoarchitectural asymmetry
224. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues